Longeveron says stem cell therapy laromestrocel reduces neuroinflammation in Phase 2a mild Alzheimer’s trial analysis

Longeveron

Longeveron

LGVN

0.00
  • Longeveron disclosed additional Phase 2a CLEAR-MIND analyses showing laromestrocel reduced MRI-measured brain free water versus placebo in mild Alzheimer’s disease.
  • Post-hoc results linked lower free water with improved cognition, quality-of-life scores, and higher brain volume, supporting an anti-inflammatory mechanism.
  • Plasma biomarkers moved versus placebo at 39 weeks, including lower neurogranin in the 25Mx4 group (p=0.023) and higher IL-13 in 25Mx1 (p=0.043).
  • Program holds FDA RMAT and Fast Track designations; Longeveron reported alignment with the FDA on a Phase 3 study design.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130705PRIMZONEFULLFEED9760934) on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.